Tuesday’s session will be partly marked by a concentration of earnings releases from most of the largest companies in the defense sector, with reports from U.S. industry leaders dominating. Today, Northrop Grumman, RTX, and France’s Thales will publish their results.
On Thursday, the earnings season will be complemented by Safran, SAAB, Dassault, and Lockheed Martin.
Thales (HO.FR)
The French industry heavyweight reported mixed first-quarter results, causing the company’s share price to fall by more than 4%.
Orders:
- Overall, orders increased by 23%, with organic growth of 27%. Growth was concentrated mainly in developed markets: 31% versus 10% in emerging markets.
- All of the increase in orders came from the “defense” segment, which grew by 71%. The “cyber” and “aerospace” segments recorded slight declines.
- Sales rose to EUR 5.31bn, up 7.2%.
Management reaffirmed its targets:
- Book-to-bill ratio above 1,
- Organic sales growth of 6–7%,
- EBITDA margin of at least 12.6%.
Valuation support may come from large contracts for orbital equipment as well as air and missile defense systems—equipment categories Europe may urgently need amid growing uncertainty over U.S. commitments to NATO.
RTX (RTX.US)
RTX Corp. reported Q1 2026 results that the market viewed as merely decent.
- Sales rose to USD 22.1bn (+9% YoY).
- Order backlog increased to USD 271bn (+25%).
- Adjusted EPS rose by 21% to USD 1.78, versus expectations of around USD 1.5.
Breaking the company down by segment:
- Sales and profitability growth were very similar across business units. Raytheon, Pratt & Whitney, and Collins Aerospace delivered 10% organic sales growth, and adjusted profit growth exceeded 20%
- Except at Collins, where profitability increased by only 6%. The company attributes this to a high exposure to the civilian segment and pricing pressure resulting from tariffs.
Management raised its FY2026 sales guidance to USD 92.5–93.5bn, with expected adjusted EPS of USD 6.7–6.9 and FCF of USD 8.25–8.75bn.
The company appears to be benefiting from several structural trends in the military equipment market and is well positioned to capitalize on them. This creates meaningful upside potential, and under current conditions the annual targets seem moderate and achievable.
Northrop Grumman (NOC.US)
The company reported mixed results, but overall investor sentiment following the release is moderately negative. The stock is down about 2% in after-hours trading.
Sales came in weak:
- Overall growth was only 4%, to USD 9.8bn.
- Despite this, the company maintained its full-year sales guidance of at least USD 43.5bn.
- Profitability was much better: the average margin increased from 6% to 10.8%.
Beyond financial guidance, Management points to:
- Aligning the company’s portfolio with new U.S. Department of Defense plans,
- Accelerating B-21 aircraft production
- Speeding up the ramp-up of the Sentinel program.
Notable items in the report include large “inter-segment eliminations,” which rose significantly, and USD 280m of expenditures (not costs) in the “Other” line. The former can be explained by the aforementioned portfolio adjustment, although the magnitude of the change may raise concerns. The latter figure remains unclear and could be linked to revaluations, contractual penalties, classified projects, or employee benefits.
Ultimately, during the conference call, Northrop appears to be asking investors for the benefit of the doubt—who, judging by the market reaction, seem willing to grant it only to a limited extent.
AllBirds: From sneakers to AI, can It work?
"AI" Layoffs: Is it a fiction?
US OPEN: Market hovering near the peaks
Daily summary: Nervous anticipation, SaaS sell-off and weak macro data
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.